胃肠间质瘤基因突变与临床病理特征、免疫组化表达分析

Analysis of Gene Mutation of Gastrointestinal Stromal Tumors and Clinical Pathological Features and Immunohistochemical Expression

目的分析胃肠间质瘤基因突变与临床病理特征、免疫组化表达情况。方法利用免疫组化方式,分析方便选取该院于2011年12月—2016年12月收治的200例GISTs者以及100例非GISTs者基因表达和突变情况。结果CD117,DOG1,IGF1R的阳性表达率为:96.0%,93.0%以及6.0%。100例非GISTs肿瘤样本CD117以及DOG1的阳性表达率为17.0%和10.0%(P<0.05)。130例存在c-KIT基因突变。GISTs者外显子表达,CD117和DOG1表达情况和cKIT以及PDGFRA基因突变无相关性,IGF1R于野生型GISTs中阳性率比突变型GISTs高(P<0.01)。不同种类的肿瘤位置之间差异有统计学意义(P<0.05)。结论联合检测CD117以及DOG1能够提升GISTs的准确程度。IGF1R可能为野生型GISTs特异性的免疫组化指标以及潜在性治疗靶点。IGF1R可能为野生型GISTs特异性的免疫组化指标以及潜在性治疗靶点。对预测GISTs者使用酪氨酸激酶抑制药物的治疗效果和预后有着相当重要的指导价值。

Objective To analyze the gene mutation of gastrointestinal stromal tumors and clinical pathological features and immunohistochemical expression. Methods The gene expression and mutation situation 200 cases of GISTs patients and 100 cases of non-GISTs patients from December 2011 to Dcember 2016 were analyzed by the immunohistochemical method.Results The positive expression rates of CD117,DOG1,IGF1 R was respectively 96.0%,93.0%, 6.0%, and the positive expression rate of CD117 and DOG1 in 100 non-GISTs patients was 17.0% and 10.0%（P〈0.05）, and 130 cases were with gene mutation, and the CD117 and DOG1 expressiona and c-KIT and PDGFRA gene mutation had no correlation, and the positive rate of IGF1 R in mild type GISTs was higher than that of mutation type GISTs（P〈0.01）, and the difference between different tumors was obvious（P〈0.05）. Conclusion The combined test of CD117 and DOG1 can improve the accuracy of GISTs,IGF1 R may be the immunohistochemical index of mild type GISTs specificity and potential treatment target, which is of important guidance value of preventing the treatment effect of oxyphenylaminopropionic acid suppressing drug and prognosis.